<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02585180</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 052-15</org_study_id>
    <nct_id>NCT02585180</nct_id>
  </id_info>
  <brief_title>Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia</brief_title>
  <official_title>Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies provide evidence for the benefit of lower respiratory tract surveillance, mostly
      by culture of endotracheal secretions, to predict bacterial pathogens (especially multi-drugs
      resistant pathogens) involved in VAP. The DEMETER study (NCT02515617) assessing the
      medico-economical impact of the subglottic secretions drainage (SSD) provides the opportunity
      to evaluate the accuracy of the subglottic secretions culture surveillance to predict
      pathogens involved in VAP (in comparison with the concomitant endotracheal secretions
      surveillance). These subglottic and tracheal secretions culture surveillance will be masked
      to the investigators of the DEMETER Study.

      This ancillary study will be performed in 14 centers participating to the DEMETER study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of adjudicated VAP in which the bacteria involved have been, previously, detected with the subglottic secretions culture surveillance.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>For each episode of VAP, bacteria involved will be compared with bacteria isolated, previously, into the subglottic secretions. This comparison will be performed by the microbiologist of each center. A bacteria isolated into the subglottic secretions will be considered as the same than the one involved in VAP if these 2 same micro-organisms have the same antibiotics susceptibility. Moreover, for the comparison, the third last subglottic secretions samples, if available, obtained before the VAP occurrence, will be taking account.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adjudicated VAP in which the bacteria involved have been, previously, detected with the tracheal secretions culture surveillance.</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>For each episode of VAP, bacteria involved will be compared with bacteria isolated, previously, into the tracheal secretions. This comparison will be performed by the microbiologist of each center. A bacteria isolated into the tracheal secretions will be considered as the same than the one involved in VAP if these 2 same microorganisms have the same antibiotics susceptibility. Moreover, for the comparison, the third last tracheal secretions samples, if available, obtained before the VAP occurrence will be taking account.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate probabilistic antibiotherapy initiated during the study by the investigators in case of adjudicated VAP</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of VAP for whom the probabilistic antibiotherapy used during the trial appeared to be empirically active</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate theoretical probabilistic antibiotherapy with the knowledge of the subglottic culture surveillance</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of adjudicated VAP for whom a theoretical probabilistic antibiotherapy would be empirically active with the knowledge of the results of the subglottic secretions samples obtained more than 3 days before the occurrence of VAP. The theoretical antibiotherapy will be determined by an independent committee unaware of the type of samples evaluated (subglottic or tracheal secretions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate theoretical probabilistic antibiotherapy with the knowledge of the tracheal culture surveillance</measure>
    <time_frame>Until weaning of mechanical ventilation, an expected average of 10 days</time_frame>
    <description>Proportion of adjudicated VAP for whom a theoretical probabilistic antibiotherapy would be empirically active with the knowledge of the results of the tracheal secretions samples obtained more than 3 days before the occurrence of VAP. The theoretical antibiotherapy will be determined by an independent committee unaware of the type of samples evaluated (subglottic or tracheal secretions).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ventilator-associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes not allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure</description>
    <arm_group_label>Period with endotracheal tubes not allowing SSD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal tubes allowing SSD</intervention_name>
    <description>In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours.</description>
    <arm_group_label>Period with endotracheal tubes allowing SSD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Invasive mechanical ventilation delivered via an endotracheal tube and expected to be
             required more than 24 hours

          -  Intubation performed in units in which the specific endotracheal tube allowing the
             subglottic secretions drainage will be available during the SSD period of the trial

          -  Information delivered

        Exclusion Criteria:

          -  Previous inclusion in the study

          -  Patients moribund at the Intensive Care Unit admission

          -  Pregnant, parturient or breast-feeding woman

          -  Patient hospitalized without consent and/or deprived of liberty by court's decision

          -  Patient under guardianship or curators

          -  Lack of social insurance

          -  Concomitant inclusion in a trial on VAP prevention

          -  Patient with no comprehension of the French language
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHD VENDEE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude LACHERADE, MD</last_name>
    <phone>33 2 51 44 60 87</phone>
    <email>jean-claude.lacherade@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU André Vésale</name>
      <address>
        <city>Montigny-le-Tilleul.</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Piagnerelli, MD, PhD</last_name>
      <phone>32 71 92 21 25</phone>
      <email>michael.piagnerelli@chu-charleroi.be</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Fameree, MD</last_name>
      <email>dominique.fameree@chu-charleroi.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Sirodot, MD</last_name>
      <phone>33 4 50 63 63 04</phone>
      <email>msirodot@ch-annecygenevois.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stephane Bland, MD</last_name>
      <phone>33 4 50 63 63 34</phone>
      <email>sbland@ch-annecygenevois.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Pajot, MD</last_name>
      <phone>33 1 34 23 14 45</phone>
      <email>olivier.pajot@ch-argenteuil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise Le Turdu, MD</last_name>
      <phone>33 1 34 23 13 04</phone>
      <email>francoise.leturdu@ch-argenteuil.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal des Portes de l'Oise</name>
      <address>
        <city>Beaumont-sur-Oise</city>
        <zip>95260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Cleophax, MD</last_name>
      <phone>33 1 39 37 15 20</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <contact_backup>
      <last_name>Geneviève Blanchard, MD</last_name>
      <email>genevieve.blanchard@ch-pontoise.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chd Vendee</name>
      <address>
        <city>La roche sur yon</city>
        <zip>85170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DESROYS DU ROURE, MD</last_name>
      <email>valerie.desroysduroure@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Docteur Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Thevenin, MD</last_name>
      <phone>33 3 21 69 12 34</phone>
      <email>dthevenin@ch-lens.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie Ledru, MD</last_name>
      <email>sledru@ch-lens.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Bellec, MD</last_name>
      <phone>33 5 63 92 81 47</phone>
      <email>f.bellec@ch-montauban.fr</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric Février, MD</last_name>
      <email>f.fevrier@ch-montauban.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Runge, MD</last_name>
      <phone>33 2 38 51 44 44</phone>
      <email>isabelle.runge@chr-orleans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Didier Poisson, MD</last_name>
      <email>didier.poisson@chr-orleans.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Pointe à Pitre les Abymes</name>
      <address>
        <city>Pointe à Pitre</city>
        <zip>97159</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Thiery, MD, PhD</last_name>
      <phone>33 5 90 89 17 74</phone>
      <email>guillaume.thiery@chu-guadeloupe.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvaine Bastian, MD</last_name>
      <phone>33 5.90.89.12.69</phone>
      <email>sylvaine.bastian@chu-guadeloupe.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHI Poissy Saint Germain</name>
      <address>
        <city>Poissy</city>
        <zip>78600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Fangio, MD</last_name>
      <phone>33 1 39 27 52 05</phone>
      <email>pfangio@chi-poissy-st-germain.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mireille Cheron, MD</last_name>
      <email>mcheron@chi-poissy-st-germain.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedric Cleophax, MD</last_name>
      <phone>33 1 30 75 43 40</phone>
      <email>cedric.cleophax@ch-pontoise.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascale Martres, MD</last_name>
      <email>pascale.martres@ch-pontoise.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion, site de Saint Denis de la Réunion</name>
      <address>
        <city>Saint Denis de la Réunion</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galliot Richard, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Olivier Belmond, MD</last_name>
      <email>olivier.belmond@chu-reunion.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH de Saint Nazaire</name>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Courouble, MD</last_name>
      <phone>33 2 72 27 80 00</phone>
      <email>p.courouble@ch-saintnazaire.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier Lemenand, MD</last_name>
      <email>o.lemenand@ch-saintnazaire.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhat Mezziani, MD, PhD</last_name>
      <phone>33 3 88 11 67 68</phone>
      <email>ferhat.meziani@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Antoine Grillon, MD</last_name>
      <phone>33 3 69 55 15 82</phone>
      <email>antoine.grillon@chru-strasbourg.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Tours, site Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Garot, MD</last_name>
      <phone>33 2 47 47 38 55</phone>
      <email>garot@med.univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Philippe Lanotte, MD</last_name>
      <email>philippe.lanotte@univ-tours.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013 Mar;39(3):365-75. doi: 10.1007/s00134-012-2759-x. Epub 2012 Nov 28. Review.</citation>
    <PMID>23188467</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventilator-associated pneumonia</keyword>
  <keyword>Surveillance</keyword>
  <keyword>Subglottic-secretions</keyword>
  <keyword>Critically ill patients</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

